Response to Infliximab Biosimilar in a Case of Reactive Arthritis: Our Experience
Published: December 1, 2019 | DOI: https://doi.org/10.7860/JCDR/2019/42695.13357
Amruta Deepak Morey, Bhushan Sevakram Madke, Adarsh Lata Singh3, Sudhir Singh, Sandeep Kulkarni
1. Junior Resident, Department of Dermatology, Venereology and Leprosy, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha,
Sawangi, Maharashtra, India.
2. Professor and Head, Department of Dermatology, Venereology and Leprosy, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha,
Sawangi, Maharashtra, India.
3. Professor, Department of Dermatology, Venereology and Leprosy, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, Sawangi,
Maharashtra, India.
4. Assistant Professor, Department of Dermatology, Venereology and Leprosy, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha,
Sawangi, Maharashtra, India.
5. Assistant Professor, Department of Dermatology, Venereology and Leprosy, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha,
Sawangi, Maharashtra, India.
Correspondence
Dr. Bhushan Sevakram Madke,
Jawaharlal Nehru Medical College, Wardha Sawangi, Wardha, Maharashtra, India.
E-mail: drbhushan81@gmail.com
[
FULL TEXT ] | [ PDF]